Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to 85.42%.

  • Xilio Therapeutics' EBITDA Margin rose 5341100.0% to 85.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 183.9%, marking a year-over-year change of. This contributed to the annual value of 918.05% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Xilio Therapeutics' EBITDA Margin is 85.42%, which was up 5341100.0% from 195.99% recorded in Q2 2025.
  • Over the past 5 years, Xilio Therapeutics' EBITDA Margin peaked at 85.42% during Q3 2025, and registered a low of 759.45% during Q4 2024.